Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Evaluation and Treatment of Primary Central Nervous System Lymphoma
Neuroradiologic evaluation, an important part of diagnosis and evaluation of the effectiveness of subsequent therapy, can be confounded by steroids administration used to alleviate symptoms of primary central nervous system lymphomas (PCNSL).
Category
- CNS Cancers
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens.
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Management of TP53 Mutated Mantle Cell Lymphoma
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients.
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Chronic Myeloid Leukemia: How to Treat During Pregnancy
Chronic myeloid leukemia (CML) can affect individuals of reproductive age, and tyrosine kinase inhibitor (TKI) therapy is known to have teratogenic effects. Discontinuing TKI therapy during pregnancy poses a risk of recurrence.
Category
- Systemic Light Chain Amyloidosis
Format
- Recorded Webcast
Credits
- 0.25 AAPA Category 1 CME credit
- 0.25 ACPE contact hours
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC contact hours
- 0.25 Participation
Cost $0.00
The Role of JAK Inhibitors in the Management of Myelofibrosis
Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF.
Category
- Myeloproliferative Neoplasms
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Amyloidosis: Diagnosis, Treatment, and Supportive Care
High rates of early mortality in newly diagnosed systemic light-chain amyloidosis (SLCA) suggest that there continues to be a delay in early diagnosis.
Category
- Systemic Light Chain Amyloidosis
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.
Category
- Acute Lymphoblastic Leukemia
- Hematologic Malignancies
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.
Category
- Acute Lymphoblastic Leukemia
- Hematologic Malignancies
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia
While blinatumomab has been utilized in the setting of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) for years, emerging data has shown promising clinical efficacy with its use as post-remission therapy.
Category
- Acute Lymphoblastic Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00